As a participant in the Amazon Services LLC Associates Program, this site may earn from qualifying purchases. We may also earn commissions on purchases from other retail websites.
According to a team of Israeli scientists, a cure for cancer could be available within as little as a year. The cure in the form of a family of drugs could be administered to patients and fully cure various types of cancer within a few weeks with no other treatments needed. What’s more, they say that this cure would not adversely affect the body’s immune system or healthy cells, so recovery could be rapid.
Ilan Morad, the CEO of Accelerated Evolution Biotechnologies (AEBi), sat down to talk with an Israeli news source, i24News. Morad explained how the new treatment, called MuTaTo (multi-target toxin), works.
“The main thing about it is multi-targeting. Most drugs today that attack cancer attack one cancer target. This is the [reason] the cancer comes back or there are a lot of side-effects. Because there is only one target, the cancer cells can very easily escape the therapy.”
"Aridor and CEO Dr. Ilan Morad, say their treatment, which they call MuTaTo (multi-target toxin) is essentially on the scale of a cancer antibiotic – a disruption technology of the highest order. The potentially game-changing anti…https://t.co/0rNlRnYzYr https://t.co/OyNBkTx6Mk
— Dan D. Aridor (@daridor) January 28, 2019
The MuTaTo therapy process targets 3 or 4 targets on cancer cells. That way, the cancer cells are unable to mutate fast enough to avoid their doom.
Looking at the science behind the drugs, The Jerusalem Post noted:
“The potentially game-changing anti-cancer drug is based on SoAP technology, which belongs to the phage display group of technologies. It involves the introduction of DNA coding for a protein, such as an antibody, into a bacteriophage – a virus that infects bacteria. That protein is then displayed on the surface of the phage. Researchers can use these protein-displaying phages to screen for interactions with other proteins, DNA sequences and small molecules.”
Instead of using phages for the anti-cancer drugs, the scientists are using a similar process with peptides, compounds of two or more amino acids linked in a chain. The multiple cancer-targeting peptides are combined with peptide toxins that kill cancer cells. The cancer doesn’t stand a chance because it can’t mutate quickly enough to avoid three targeted receptors at once. The cells are killed before they are able to detoxify.
“Instead of attacking receptors one at a time, we attack receptors three at a time – not even cancer can mutate three receptors at the same time,” said Morad.
Another strategy that cancer cells use to avoid treatment is blocking access to large molecules similar to erecting a shield. However, MuTaTo is able to get around this defense mechanism as well. The peptides are small and lack a rigid structure that the cancer cells could block.
The Jerusalem Post noted:
“MuTaTo acts like an octopus or a piece of spaghetti and can sneak into places where other large molecules cannot reach.”
The scientists equate the idea of using multiple targets to the successful idea of giving a drug cocktail to AIDS patients.
“We used to give AIDS patients several drugs, but we would administer them one at a time,” Morad explained. “During the course of treatment, the virus mutated, and the AIDS started attacking again. Only when patients started using a cocktail, were they able to stop the disease.”
When asked if the treatment will be effective on humans, he explained that the scientists have run tests on human cancer cells and believe the results are promising and replicable. Further, since the treatment is specific to cancer cells it results in fewer side effects and prevents cells from becoming cancerous again – all without suffering.
“The treatment would be patient-friendly like an antibiotic,” said Dr. Morad.
Elaborating on the process, Morad says doctors would analyze the specific cancer found in patients and create a customized therapy to eradicate the dangerous cells. Each patient would require a unique combination of peptides created to target their particular cancer cells.
Understandably, the scientist’s claims are being met with skepticism, excitement, and enthusiasm, as the thought of a worldwide cure to cancer just seems too good to be true. The International Agency for Research on Cancer estimates there are 18.1 million new cancer cases every year. That translates to every sixth death in the world. Now imagine if that were no longer the case. Imagine saving that many people from needless suffering and death.
Currently, AEBi is in the clinical stage of testing on cancer cells in small animals. Next, they will move to test MuTaTo on larger animals and ultimately humans. Dr. Morad believes that the treatment could be ready for clinical trials in humans in as little as one year, depending on how quickly they can finance the research.
We sure hope there is substance behind these as-of-yet unproven claims. It does give us a sense of hope that a cure could be coming in the near future. Having hope is never a bad thing, and we hope this cure is legit.
See the interview with Dr. Morad below:
Featured image: Cancer cells illustration via Flickr, NIH Image Gallery, public domain